Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Zynlonta (loncastuximab tesirine-lpyl)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Mitsubishi Tanabe, Overland ADCT BioPharma, SOBI

Drug class:

DNA replication inhibitor, CD19-targeted antibody-drug conjugate

Related drugs:

‹

›

No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	loncastuximab tesirine-lpyl Sensitive: A1 - Approval loncastuximab tesirine-lpyl Sensitive : A1	loncastuximab tesirine-lpyl Sensitive: A1 - Approval loncastuximab tesirine-lpyl Sensitive : A1
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	loncastuximab tesirine-lpyl Sensitive: C3 – Early Trials loncastuximab tesirine-lpyl Sensitive : C3	loncastuximab tesirine-lpyl Sensitive: C3 – Early Trials loncastuximab tesirine-lpyl Sensitive : C3
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	loncastuximab tesirine-lpyl Sensitive: C3 – Early Trials loncastuximab tesirine-lpyl Sensitive : C3	loncastuximab tesirine-lpyl Sensitive: C3 – Early Trials loncastuximab tesirine-lpyl Sensitive : C3
CD19 underexpression	Diffuse Large B Cell Lymphoma	CD19 underexpression	Diffuse Large B Cell Lymphoma	loncastuximab tesirine-lpyl Sensitive: C3 – Early Trials loncastuximab tesirine-lpyl Sensitive : C3	loncastuximab tesirine-lpyl Sensitive: C3 – Early Trials loncastuximab tesirine-lpyl Sensitive : C3
BRCA mutation	Diffuse Large B Cell Lymphoma	BRCA mutation	Diffuse Large B Cell Lymphoma	loncastuximab tesirine-lpyl Sensitive: D – Preclinical loncastuximab tesirine-lpyl Sensitive : D	loncastuximab tesirine-lpyl Sensitive: D – Preclinical loncastuximab tesirine-lpyl Sensitive : D
CD19 expression	Non-Hodgkin’s Lymphoma	CD19 expression	Non-Hodgkin’s Lymphoma	loncastuximab tesirine-lpyl + IGM-2323 Sensitive: D – Preclinical loncastuximab tesirine-lpyl + IGM-2323 Sensitive : D	loncastuximab tesirine-lpyl + IGM-2323 Sensitive: D – Preclinical loncastuximab tesirine-lpyl + IGM-2323 Sensitive : D
CD20 expression	Non-Hodgkin’s Lymphoma	CD20 expression	Non-Hodgkin’s Lymphoma	loncastuximab tesirine-lpyl + IGM-2323 Sensitive: D – Preclinical loncastuximab tesirine-lpyl + IGM-2323 Sensitive : D	loncastuximab tesirine-lpyl + IGM-2323 Sensitive: D – Preclinical loncastuximab tesirine-lpyl + IGM-2323 Sensitive : D